| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Adaptive Biotechnologies Corporation$21.06
-0.93 (-4.27%)
C 42Pipeline Score Overvalued Biotech · Commercial
Market Cap
2.42 B
EPS
-0.32
P/E Ratio
-46.83 $
Value Trade
34.94 M
SEC Financials
Q1 2026Dilution Risk
Revenue
70.87 M
R&D Expenses
23.62 M
Operating CF
-9.54 M
Total Assets
505.94 M
Total Liabilities
281.70 M
Equity
216.34 M
D/E Ratio
12,345
7.35 %
Week
-3.88 %
1 Month
-12.76 %
3 Month
-14.74 %
6 Month
-61.96 %
5 Year
-64.42 %
All Time
Cash Data
Cash Position
218.33 M
Monthly Burn
3.18 M
Runway
66.7 mo
Burn Trend
SEC Filing
May 5, 2026
Overview
Volume
1.91 M
52 Week Range
9.78 - 20.76
% held by Insiders
3.41 %
% held by Institutions
95.08 %
Enterprise Value
2.42 B
Total Shares
159.96 M
Short %
9.39 %
Float Shares
120.93 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Adaptive Biotechnologies Corporation
264Total events
3Upcoming
29Tier-1 (high impact)
2019 – 2026Coverage
Upcoming catalysts 3
Event history 261
Jun 17, 2026
Jun 15, 2026
▼Equity OfferingCorporate
Announced proposed offering of $250M convertible senior notes due 2031
Jun 3, 2026
◆Oral PresentationPresentation
William Blair 46th Annual Growth Stock Conference Presentation
May 29, 2026
◆Oral PresentationclonoSEQPresentation
MRD-guided therapy duration/discontinuation data from BOVen-∆MRD400 presented at ASCO/EHA 2026
chronic lymphocytic leukemiasource ↗
May 29, 2026
▲Full ResultsclonoSEQClinical Data
Final analysis from CEPHEUS trial showing higher rates of sustained MRD negativity
multiple myelomasource ↗
May 28, 2026
◆Oral PresentationPresentation
Craig-Hallum 23rd Annual Institutional Investor Conference 1x1 Meetings
Feb 2026
Jan 12, 2026
Drug Pipeline Intelligence
C42
Pipeline Score $879M
Pipeline ValueOvervalued
Valuation Signal8
Drugs Scored0.4x
rNPV / MCap Top 62%
Small Cap (rank 347 of 911)
Percentile RankAdaptive Biotechnologies Corporation carries a moderate pipeline score (42/100), with $1.4B risk-adjusted pipeline value, led by Ceftaroline in Community-acquired Pneumonia, Influenza, COVID-19 (Phase 3).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ceftaroline Small molecule | Community-acquired Pneumonia, Influenza, COVID-19 | Phase 3 | NCT02735707 | 62% | $627M | RECRUITING | 20,000 | - | - | Feb 1, 2028 | - | May 21, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
clonoSEQ | B-cell acute lymphoblastic leukemia (B-ALL) | Phase 2 | 2025-12-08 | 51 patients who were NGS MRD negative and received a non-TBI regimen Read More | Adaptive Biotechnologies Showcases Leadership in Hematology-Oncology MRD with New clonoSEQ® Data Driving Treatment Interventions at 2025 ASH Annual Meeting Read More | |
clonoSEQ | B-cell acute lymphoblastic leukemia (B-ALL) | Phase 2 | 2025-12-08 | 51 patients who were NGS MRD negative and received a non-TBI regimen Read More | Adaptive Biotechnologies Showcases Leadership in Hematology-Oncology MRD with New clonoSEQ® Data Driving Treatment Interventions at 2025 ASH Annual Meeting Read More | |
clonoSEQ | B-cell acute lymphoblastic leukemia (B-ALL) | Phase 2 | 2025-12-08 | 51 patients who were NGS MRD negative and received a non-TBI regimen Read More | Adaptive Biotechnologies Showcases Leadership in Hematology-Oncology MRD with New clonoSEQ® Data Driving Treatment Interventions at 2025 ASH Annual Meeting Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in ADPT
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
ADPT Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
ADPT▼ -4.3%today
Adaptive Biotechnologies to Report Second Quarter 2026 Financial Results on July 29, 2026
Adaptive Biotechnologies Corporation will release its second quarter 2026 financial results on July 29, 2026, after market close. A conference call will follow at 1:30 p.m. PT to discuss the results. The webcast will be available live and archived for later access, showcasing the company's commitment to investor relations.
Read more →ADPTAdaptive Biotechnologies Corporation Prices Upsized $300 Million Convertible Senior Notes Offering
Adaptive Biotechnologies Corporation has announced the pricing of an upsized $300 million offering of convertible senior notes due in 2031. The proceeds will be utilized to repay existing agreements, repurchase shares, and for general corporate purposes. The offering is set to close on June 22, 2026, with a conversion rate of 41.48 shares per $1,000 principal amount.
Read more →ADPTAdaptive Biotechnologies Announces Plan to Separate Its MRD and Immune Medicine Businesses
Adaptive Biotechnologies plans to separate its Minimal Residual Disease (MRD) and Immune Medicine businesses to enhance growth and value creation. The MRD segment has reached profitability and expanded its clinical utility, while Immune Medicine is advancing its discovery capabilities. The company aims to finalize its separation strategy by the end of 2026.
Read more →ADPTAdaptive Biotechnologies Corporation Announces Proposed Convertible Senior Notes Offering
Adaptive Biotechnologies Corporation has announced a proposed offering of $250 million in convertible senior notes due 2031. The proceeds will be used to repay an existing purchase agreement, repurchase common stock, and support corporate initiatives in the Minimal Residual Disease (MRD) sector. The offering is subject to market conditions and includes an option for initial purchasers to buy additional notes.
Read more →ADPTAt ASCO and EHA 2026, New Data Reinforce the Pivotal Role of clonoSEQ® MRD Testing Across Hematology Clinical Practice and Research
Adaptive Biotechnologies announced that its clonoSEQ MRD testing will feature prominently at the ASCO and EHA conferences. The data presented highlights clonoSEQ's pivotal role in assessing treatment responses and guiding therapy decisions in hematologic malignancies. The technology is increasingly recognized as essential for modern oncology care, with significant implications for patient management.
Read more →ADPTAdaptive Biotechnologies to Participate in Upcoming Investor Conferences
Adaptive Biotechnologies Corporation (Nasdaq: ADPT) has announced its participation in upcoming investor conferences, including the Craig-Hallum 23rd Annual Institutional Investor Conference in Minneapolis and the William Blair 46th Annual Growth Stock Conference in Chicago. At these events, the company aims to engage with investors and showcase its advancements in leveraging the adaptive immune system for clinical applications. The presentation at the William Blair conference is scheduled for June 3rd, with a live and archived webcast available on the company's website.
Read more →ADPTAdaptive Biotechnologies Reports First Quarter 2026 Financial Results
Adaptive Biotechnologies reported a strong financial performance for Q1 2026, with revenues reaching $70.9 million, a 35% increase from the previous year. The Minimal Residual Disease (MRD) segment was a significant contributor, growing 53%. However, the company also reported a net loss of $20 million and a decline in Immune Medicine revenue by 57%. The company has raised its full-year MRD revenue guidance to between $260 million and $270 million.
Read more →ADPTAdaptive Biotechnologies to Report First Quarter 2026 Financial Results on May 5, 2026
Adaptive Biotechnologies Corporation will announce its financial results for the first quarter of 2026 on May 5, 2026, after market close. A conference call will follow, allowing management to discuss the results. The company specializes in leveraging the adaptive immune system for disease diagnosis and treatment.
Read more →ADPTAdaptive Biotechnologies Reports Fourth Quarter and Full Year 2025 Financial Results
Adaptive Biotechnologies reported strong financial results for Q4 and full year 2025, achieving a 51% revenue increase in Q4 and a 55% increase for the year. The company reached profitability in its Minimal Residual Disease (MRD) business and expects continued growth in 2026. However, it also reported a net loss of $13.6 million for Q4 2025, despite significant revenue growth.
Read more →ADPTAdaptive Biotechnologies to Participate in Upcoming Investor Conferences - January 27, 2026
Adaptive Biotechnologies Corporation announced its participation in upcoming investor conferences. The company focuses on leveraging the adaptive immune system for clinical products aimed at diagnosing and treating diseases. Interested investors can access live and archived webcasts on the company's website. Adaptive continues to develop its proprietary immune medicine platform.
Read more →ADPTAdaptive Biotechnologies to Report Fourth Quarter and Full Year 2025 Financial Results on February 5, 2026
Adaptive Biotechnologies Corporation will announce its financial results for Q4 and the full year 2025 on February 5, 2026. The announcement includes a conference call that will be webcasted, allowing investors to access the information live. The company emphasizes its commitment to leveraging the adaptive immune system for disease diagnosis and treatment.
Read more →ADPT▲ +15.9%on this news
Adaptive Biotechnologies Announces Preliminary Fourth Quarter and Full Year 2025 Results Full year MRD revenue growth of 46% driven by clonoSEQ testing volume SEATTLE
Adaptive Biotechnologies announced preliminary results for the fourth quarter and full year ended December 31, 2025, reporting a 46% growth in Minimal Residual Disease (MRD) revenue driven by clonoSEQ testing volume. CEO Chad Robins highlighted the strong performance and anticipated continued momentum into 2026, focusing on MRD testing leadership and profitability. However, the results are preliminary and still subject to audit, indicating potential changes in final figures. The company's complete financial results will be released during an earnings call in February 2026.
Read more →ADPTAdaptive Biotechnologies to Present at the 44th Annual J.P. Morgan Healthcare Conference
Adaptive Biotechnologies Corporation announced its participation in the 44th Annual J.P. Morgan Healthcare Conference in San Francisco. Scheduled for January 12, 2026, the presentation will showcase their developments in utilizing the adaptive immune system for disease diagnosis and treatment. Interested individuals can access a live and archived webcast of the presentation via the company's website. This participation signifies the company's commitment to advancing its clinical products and engaging with industry stakeholders.
Read more →ADPTAdaptive Biotechnologies Announces Two Immune Receptor Licensing Agreements with Pfizer
Adaptive Biotechnologies has entered into two licensing agreements with Pfizer to utilize its T-cell receptor (TCR) discovery platform. The first agreement focuses on identifying disease-specific TCRs in rheumatoid arthritis, while the second allows Pfizer access to Adaptive's TCR-antigen datasets for broader immunology research. These collaborations could lead to significant advancements in therapeutic development.
Read more →ADPTAdaptive Biotechnologies to Participate in Jefferies Fireside Chat Series on Minimal Residual Disease
Adaptive Biotechnologies Corporation is set to participate in a Jefferies fireside chat focusing on Minimal Residual Disease in Hematology/Oncology. Dr. Harlan Robins and Susan Bobulsky will discuss the clonoSEQ assay technology in detail during the call scheduled for December 11, 2025. This event aligns with the company’s goal to leverage the adaptive immune system for innovative disease diagnostics and treatments.
Read more →ADPTAdaptive Biotechnologies Showcases Leadership in Hematology-Oncology MRD with New clonoSEQ® Data Driving Treatment Interventions at 2025 ASH Annual Meeting
Adaptive Biotechnologies highlighted the increasing use of its clonoSEQ test at the 2025 ASH Annual Meeting, with 17 abstracts showcasing its role in guiding treatment decisions for blood cancer patients. The phase II EndRAD study demonstrated improved survival outcomes for B-ALL patients using non-TBI conditioning. clonoSEQ is recognized for its precision in monitoring measurable residual disease.
Read more →ADPTAdaptive Biotechnologies Showcases Leadership in Hematology-Oncology MRD with New clonoSEQ Data Driving Treatment Interventions at 2025 ASH Annual Meeting
Adaptive Biotechnologies showcased significant advancements in hematology-oncology treatment at the 2025 ASH Annual Meeting, emphasizing the growing interventional use of their clonoSEQ test. The phase II EndRAD study highlighted superior outcomes for NGS MRD negative patients undergoing non-TBI conditioning prior to transplantation. With 90 abstracts featuring clonoSEQ data, the company illustrated its impact on guiding treatment interventions across various blood cancers. This year's data further solidified clonoSEQ's position as a leader in MRD monitoring, aiding clinical decision-making and improving patient care.
Read more →ADPT▲ +9.9%on this news
Adaptive Biotechnologies Announces Nearly 90 Abstracts Featuring clonoSEQ MRD Testing Across a Range of Blood Cancers to be Presented at the 67th ASH Annual Meeting
Adaptive Biotechnologies announced the inclusion of its clonoSEQ MRD testing in 89 abstracts at the 67th Annual Meeting of the American Society of Hematology. This recognition highlights clonoSEQ's significance in assessing measurable residual disease across various blood cancers, including multiple myeloma and leukemia. With 36 oral presentations, the data demonstrates how clonoSEQ informs treatment decisions in real-world clinical practice. The continued expansion of clonoSEQ in clinical trials further emphasizes its importance in developing new therapeutic approaches.
Read more →ADPT▼ -11.5%on this newsshared move
Adaptive Biotechnologies Reports Third Quarter 2025 Financial Results
Adaptive Biotechnologies reported strong financial results for Q3 2025, with revenues reaching $94 million, a 102% increase from the previous year. The company achieved profitability in its Minimal Residual Disease (MRD) business and reported positive cash flow. Despite increased operating expenses, the overall performance indicates significant growth and progress in their clinical programs.
Read more →ADPT▲ +9.8%on this news
Adaptive Biotechnologies to Report Third Quarter 2025 Financial Results on November 5, 2025
Adaptive Biotechnologies Corporation has announced it will report its third quarter 2025 financial results on November 5, 2025, after market close. Management will conduct a webcast starting at 1:30 p.m. Pacific Time to discuss the results. This indicates the company's ongoing involvement in the biotechnology sector and its commitment to transparency with its investors.
Read more →ADPTAdaptive Biotechnologies to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference
Adaptive Biotechnologies Corporation will participate in the Morgan Stanley 23rd Annual Global Healthcare Conference in New York. The management is set to engage in a fireside chat on September 10, 2025. This event provides a platform for the company to discuss its advancements in immune medicine and connect with investors.
Read more →ADPTAdaptive Biotechnologies Reports Second Quarter 2025 Financial Results SEATTLE
Adaptive Biotechnologies reported strong financial results for the second quarter of 2025, with a revenue of $58.9 million, marking a 36% increase from the previous year. The company's Minimal Residual Disease (MRD) segment showed particularly promising growth, achieving a 42% revenue increase and profitability for the first time. As a result, the firm raised its full-year MRD revenue guidance. However, the company still recorded a net loss of $25.6 million, though this represents an improvement from the same quarter last year.
Read more →ADPTAdaptive Biotechnologies to Report Second Quarter 2025 Financial Results on August 5, 2025
Adaptive Biotechnologies Corporation has announced that it will report its financial results for the second quarter of 2025 on August 5, 2025. The financial results will be revealed after market close, followed by a webcast conference call for stakeholders. The company focuses on transforming the diagnosis and treatment of diseases through its proprietary immune medicine platform, particularly in areas such as cancer and autoimmune disorders. Live audio of the event can be accessed via their website, with an archived version available shortly thereafter.
Read more →ADPTAdaptive Biotechnologies and Flatiron Health Announce Integration of clonoSEQ® MRD Testing into OncoEMR®
Adaptive Biotechnologies and Flatiron Health have announced the integration of clonoSEQ MRD testing into Flatiron's OncoEMR platform. This integration facilitates easier access to MRD testing for over 4,500 clinicians across the U.S., enhancing patient care in community oncology. The collaboration aims to improve treatment decisions and patient outcomes by providing real-time insights into disease status.
Read more →ADPTAdaptive Biotechnologies Highlights New Data at 2025 ASCO Annual Meeting and EHA 2025 Congress Demonstrating How clonoSEQ® MRD Assessment is Optimizing Patient Care and Drug Development in Lymphoid Cancers
Adaptive Biotechnologies announced that its clonoSEQ MRD assessment will be featured in 30 presentations at the ASCO Annual Meeting and EHA Congress. This includes 14 oral presentations showcasing new data on its clinical actionability in multiple myeloma and chronic lymphocytic leukemia. The company emphasizes the significant role of clonoSEQ in enhancing patient care and drug development in lymphoid cancers.
Read more →ADPTAdaptive Biotechnologies to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
Adaptive Biotechnologies Corporation will participate in the Goldman Sachs 46th Annual Global Healthcare Conference in Miami, Florida. The event will feature a fireside chat with the company's management on June 11th. Interested individuals can access a live and archived webcast of the presentation on the company’s website. Adaptive Biotechnologies aims to transform disease diagnosis and treatment through its proprietary immune medicine platform.
Read more →ADPTAdaptive Biotechnologies Reports First Quarter 2025 Financial Results SEATTLE
Adaptive Biotechnologies has reported its financial results for the first quarter of 2025, posting a revenue of $52.4 million, which is a 25% increase year-over-year. The Minimal Residual Disease (MRD) business showed a substantial growth of 34% and contributed significantly to the overall revenue. The company also announced an increase in its full year MRD revenue guidance and noted a reduction in operating expenses. However, it reported a net loss of $29.8 million for the quarter, despite improvements from the prior year.
Read more →ADPT▼ -7.8%on this news
Adaptive Biotechnologies to Report First Quarter 2025 Financial Results on May 1, 2025
Adaptive Biotechnologies Corporation has announced that it will report its financial results for Q1 2025 on May 1, 2025, following market close. A conference call will accompany the report, allowing stakeholders to discuss the results in detail. The company specializes in translating the adaptive immune system's genetics into clinical products aimed at diagnosing and treating various diseases, including cancer and autoimmune disorders.
Read more →ADPTAdaptive Biotechnologies Receives Expanded Medicare Coverage of clonoSEQ for Surveillance in Mantle Cell Lymphoma
Adaptive Biotechnologies has announced the expansion of Medicare coverage for its clonoSEQ test, now including single time point testing for patients with mantle cell lymphoma. This allows patients to monitor for disease recurrence every six months for up to five years after treatment. The coverage expansion underscores the clinical significance of clonoSEQ in managing patient outcomes and could pave the way for broader surveillance testing in other indications. The updated payment rate for clonoSEQ testing has also been established at $2,007 per test in accordance with Medicare's Clinical Laboratory Fee Schedule.
Read more →ADPT▲ +12.3%on this news
Adaptive Biotechnologies Launches Assay Enhancements to Increase clonoSEQ Sensitivity for Clinical MRD Detection in Diffuse Large B-Cell Lymphoma
Adaptive Biotechnologies announced enhancements to its clonoSEQ assay for measurable residual disease detection in diffuse large B-cell lymphoma (DLBCL). The improved assay features a 7-fold increase in sensitivity, allowing for better assessment of patients' MRD status. This upgrade has been approved by New York State's Clinical Lab Evaluation Program and is already being utilized in clinical trials. The clonoSEQ assay remains the only MRD test for DLBCL that is clinically available and covered by Medicare, solidifying its role in patient management.
Read more →ADPTAdaptive Biotechnologies Reports Fourth Quarter and Full Year 2024 Financial Results SEATTLE
Adaptive Biotechnologies has reported its fourth quarter and full year 2024 financial results, highlighting significant growth in its Minimal Residual Disease (MRD) business with a 42% revenue increase. The company generated $179 million in total revenue for 2024, while experiencing a substantial decline in its Immune Medicine sector by 51%. Despite a notable reduction in operating expenses and increased cash position, Adaptive reported sizable net losses, indicating a need for continued focus on achieving profitability and growth in its therapeutic pipeline.
Read more →ADPT▲ +7.5%on this news
Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2024 Financial Results on February 11, 2025
Adaptive Biotechnologies Corporation announced that it will report its fourth quarter and full year 2024 financial results on February 11, 2025. The company is known for its work in translating the genetics of the adaptive immune system into clinical applications. Following the financial results, a conference call will be held to discuss the outcomes, available for live audio through the company’s website. This demonstrates the company's ongoing efforts in transparency and engagement with investors.
Read more →ADPT▼ -6%on this news
Adaptive Biotechnologies and NeoGenomics Partner to Expand Access to Personalized Disease Monitoring for Blood Cancer Patients
Adaptive Biotechnologies has partnered with NeoGenomics to enhance minimal residual disease (MRD) monitoring for blood cancer patients. The collaboration includes the integration of Adaptive's clonoSEQ, the only FDA-cleared IVD for MRD detection, with NeoGenomics' comprehensive testing services. This partnership aims to provide personalized treatment strategies and facilitate better monitoring and risk assessment for patients with multiple myeloma and other blood cancers. Implementation efforts will begin soon, although specific financial details of the agreement remain undisclosed.
Read more →ADPTAdaptive Biotechnologies Announces Clinical Lab Fee Schedule Rate of $2,007 for clonoSEQ Test for Minimal Residual Disease Assessment is Effective as of January 1st, 2025
Adaptive Biotechnologies announced that the new Medicare Clinical Laboratory Fee Schedule rate for its clonoSEQ test for minimal residual disease assessment has been set at $2,007, effective January 1, 2025. This rate is part of a gapfill pricing process, which ensures fair pricing for novel diagnostic tests. The updated pricing will enable broader adoption and increase patient access to essential MRD testing. Adaptive plans to utilize this finalized rate to enhance payer agreements and expand coverage for additional indications.
Read more →ADPTAdaptive Biotechnologies to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Adaptive Biotechnologies Corporation announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. Scheduled for January 14th, management will present insights into the company's advancements in harnessing the adaptive immune system for disease diagnosis and treatment. The company aims to innovate through its immune medicine platform, which underpins its clinical products and pipeline in addressing various diseases. A live webcast of the presentation will be available for interested parties.
Read more →ADPTAdaptive Biotechnologies Announces New Data at the 66th ASH Annual Meeting Highlighting Advances in MRD Testing with clonoSEQ and Its Impact on Blood Cancer Treatment Decisions
Adaptive Biotechnologies announced new data from the 66th ASH Annual Meeting, highlighting the significance of its clonoSEQ test in managing blood cancers. The data indicated that the test could help tailor treatment decisions, particularly showing that autologous hematopoietic cell transplantation (auto-HCT) may not benefit certain patients with undetectable minimal residual disease (uMRD). Additionally, the findings from several studies underscored the potential of clonoSEQ in enhancing patient outcomes and informing treatment strategies for various blood cancers.
Read more →ADPTAdaptive Biotechnologies Announces Over 65 Abstracts Featuring clonoSEQ MRD Testing Across a Range of Blood Cancers to be Presented at the 66th ASH Annual Meeting
Adaptive Biotechnologies Corporation announced that their clonoSEQ MRD testing will feature in over 65 abstracts at the upcoming ASH Annual Meeting. This inclusion covers multiple blood cancers and underlines the test's role as a primary endpoint in clinical trials. The company's leadership expressed optimism about the widespread acceptance and utilization of clonoSEQ in clinical decision-making. The test is recognized for its high sensitivity and effectiveness in monitoring treatment responses.
Read more →ADPTAdaptive Biotechnologies Receives Expanded Medicare Coverage of clonoSEQ for Assessing Measurable Residual Disease in Mantle Cell Lymphoma
Adaptive Biotechnologies announced that Medicare has expanded coverage for clonoSEQ, the first assay for assessing measurable residual disease (MRD) in mantle cell lymphoma (MCL). This coverage allows for improved monitoring and management of MCL patients, who often have recurrent disease after treatment. The updated policy extends to all patients regardless of therapy line, enhancing access to this critical diagnostic tool in the Medicare demographic. The clonoSEQ testing process offers a minimally invasive option to monitor MRD effectively, aiming to improve overall patient outcomes.
Read more →ADPTAdaptive Biotechnologies Reports Third Quarter 2024 Financial Results SEATTLE
Adaptive Biotechnologies reported its financial results for the third quarter of 2024, indicating a significant revenue growth of 22%, totaling $46.4 million. The company's Minimal Residual Disease (MRD) business was a major contributor, with a 52% increase in revenue year-over-year. However, the Immune Medicine sector saw a decline, with a 32% drop in revenue. Despite the overall positive financial performance and adjusted guidance, the company still recorded a net loss of $32.1 million for the quarter.
Read more →ADPTAdaptive Biotechnologies to Report Third Quarter 2024 Financial Results on November 7, 2024
Adaptive Biotechnologies Corporation announced that it will report its financial results for the third quarter of 2024 on November 7, 2024. The announcement includes details about a conference call to discuss these results, which will take place after market close. The company emphasizes its commitment to improving diagnosis and treatment of diseases through its proprietary immune medicine platform. The webcast of the call will be available live and archived for later access on their website.
Read more →ADPTAdaptive Announces IVDR Certification for clonoSEQ in European Union
Adaptive Biotechnologies Corporation announced that clonoSEQ has received IVDR certification in the European Union, making it the first certified test for detecting minimal residual disease in lymphoid malignancies. This certification allows European labs to offer clonoSEQ MRD testing, expanding access and supporting clinical trials. The assay provides real-time insights into disease progression and improves treatment personalization for blood cancer patients. clonoSEQ is already utilized in numerous active biopharma-sponsored trials, underscoring its importance in modern oncology.
Read more →ADPTAdaptive Biotechnologies to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
Adaptive Biotechnologies Corporation (Ticker: ADPT) has announced its participation in the Morgan Stanley 22nd Annual Global Healthcare Conference, scheduled for September 6th. During the conference, company management will engage in a fireside chat, accessible via a live and archived webcast on their website. Adaptive Biotechnologies focuses on leveraging the adaptive immune system to develop diagnostic and therapeutic products, with a commercial pipeline that addresses various diseases including cancer and autoimmune disorders.
Read more →ADPTAdaptive Biotechnologies Reports Second Quarter 2024 Financial Results SEATTLE
Adaptive Biotechnologies reported its financial results for Q2 2024, showcasing a 36% increase in Minimal Residual Disease (MRD) revenue, leading to $43.2 million in total revenue for the quarter. Although the overall revenue saw a decrease from the previous year, the company has reduced operating expenses, resulting in an improved cash burn situation. The company remains optimistic about its MRD business and updated its revenue guidance, indicating anticipated growth. However, it also reported a significant decline in Immune Medicine revenue and continues to operate at a loss.
Read more →ADPT▲ +11.1%on this news· ran to +27% by day 3
Adaptive Biotechnologies to Report Second Quarter 2024 Financial Results on August 1, 2024
Adaptive Biotechnologies Corporation announced that it will report its financial results for the second quarter of 2024 on August 1, 2024, after market close. A conference call will follow the release, starting at 1:30 p.m. Pacific Time. The company focuses on leveraging the adaptive immune system to develop clinical products for diagnosing and treating various diseases. Interested parties can access the live webcast through the company's website, which will also be available for replay afterward.
Read more →ADPTAdaptive Biotechnologies Announces Data Supporting the Clinical Benefits of MRD Assessment with clonoSEQ To Be Presented at the Upcoming 2024 ASCO Annual Meeting and EHA2024 Hybrid Congress
Adaptive Biotechnologies has announced that data supporting the clinical benefits of its clonoSEQ test for measurable residual disease (MRD) assessment will be presented at both the ASCO Annual Meeting and the EHA Hybrid Congress. The presented research aims to reinforce clonoSEQ's significance in personalizing blood cancer treatment and monitoring patient responses. Key highlights include studies on pediatric acute lymphoblastic leukemia and adult multiple myeloma that illustrate the potential of clonoSEQ for less invasive monitoring and improved patient outcomes. This development marks a significant step forward in the treatment landscape for blood cancers.
Read more →ADPTAdaptive Biotechnologies to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
Adaptive Biotechnologies Corporation has announced its participation in the Goldman Sachs 45th Annual Global Healthcare Conference, which will take place on June 11th in Miami, FL. The company's management will engage in a fireside chat, providing insights into their cutting-edge immune medicine platform focused on diagnosing and treating diseases. Stakeholders can access a live and archived webcast of the presentation through the company's website. This event represents a strategic opportunity for Adaptive to enhance its profile in the healthcare sector.
Read more →ADPTAdaptive Biotechnologies Reports First Quarter 2024 Financial Results SEATTLE
Adaptive Biotechnologies reported its financial results for Q1 2024, showcasing significant growth in its Minimal Residual Disease (MRD) segment but a decline in Immune Medicine revenue. The company's overall revenue increased to $41.9 million, driven largely by a 52% growth in the MRD business. Despite a substantial net loss of $47.5 million, the firm is optimistic about its future prospects, bolstered by strong cash reserves and favorable FDA decisions.
Read more →ADPT▼ -11.3%on this news
Adaptive Biotechnologies to Report First Quarter 2024 Financial Results on May 7, 2024
Adaptive Biotechnologies Corporation announced it will report its financial results for the first quarter of 2024 after market close on May 7, 2024. Following the announcement, company management will host a conference call to discuss the results. The event underscores the company's efforts to maintain transparency with its investors, highlighting its ongoing commitment to the development of immune-driven clinical products. Information regarding the webcast will be made available on the company's website.
Read more →ADPTAdaptive Biotechnologies Provides Strategic Review Update and Announces Preliminary First Quarter 2024 Revenue Announces CFO transition SEATTLE
Adaptive Biotechnologies provided an update on its strategic review and announced preliminary revenue results for Q1 2024, which indicate a 12% increase from the previous year. The company plans to restructure its MRD and Immune Medicine businesses to enhance independence while maintaining a strong capital position. Additionally, a transition in leadership is underway as CFO Tycho Peterson departs the company, with Kyle Piskel stepping into the role. The final financial results are still being prepared and may differ from the preliminary reports.
Read more →ADPTAdaptive Biotechnologies to Hold a Business Update Conference Call and Webcast on April 2, 2024
Adaptive Biotechnologies Corporation has announced that it will hold a business update conference call and webcast on April 2, 2024. The event is scheduled to take place after market close at 1:30 PM Pacific Time. Interested parties can access the live audio through the Investors section of the company's website. The event will also be archived for replay within 24 hours, allowing stakeholders to stay informed about the company's advancements and goals.
Read more →ADPTAdaptive Biotechnologies to Present at the TD Cowen 44th Annual Healthcare Conference
Adaptive Biotechnologies Corporation will be presenting at the TD Cowen 44th Annual Healthcare Conference in Boston on March 4, 2024. The presentation will highlight the company's efforts in leveraging the biology of the adaptive immune system to develop clinical products. Attendees can access a live and archived webcast via the company’s website. This event underscores Adaptive Biotechnologies' ongoing commitment to innovative therapies for various diseases, including cancer and autoimmune disorders.
Read more →ADPT▲ +8.8%on this news
Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2023 Financial Results SEATTLE
Adaptive Biotechnologies reported its financial results for Q4 and full year 2023, highlighting a 53% growth in clonoSEQ tests delivered. However, the company also faced challenges, including a net loss increase and an overall revenue decline of 8% year-over-year. While the MRD business showed promising growth, the Immune Medicine segment suffered a significant revenue decrease. Future guidance suggests expectations for modest growth in MRD revenue for 2024, with details to be discussed in an upcoming conference call.
Read more →ADPTAdaptive Biotechnologies to Report Fourth Quarter and Full Year 2023 Financial Results on February 14, 2024
Adaptive Biotechnologies Corporation has announced it will report its financial results for the fourth quarter and full year of 2023 on February 14, 2024, after market close. A corresponding conference call, which investors can access via webcast, is scheduled to begin at 1:30 p.m. Pacific Time. The company emphasizes the importance of the adaptive immune system in the development of diagnostic and therapeutic products for diseases including cancer and autoimmune disorders.
Read more →ADPTAdaptive Biotechnologies to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Adaptive Biotechnologies Corporation announced its participation in the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, scheduled for January 9th. The presentation will focus on the company's innovative approach to leveraging the adaptive immune system for disease diagnosis and treatment. Attendance at this notable conference signals the company's ongoing commitment to advancing its clinical products and potentially attracting investor interest. Stakeholders can access the live and archived presentation on the company's website.
Read more →ADPTAdaptive Biotechnologies Announces New Data Highlighting the Clinical Relevance of MRD Testing with clonoSEQ in Patients with Blood Cancers at the 65th ASH Annual Meeting
Adaptive Biotechnologies announced new data at the 65th ASH Annual Meeting, highlighting the clinical relevance of its clonoSEQ test for minimal residual disease (MRD) assessment in blood cancers. The test shows promise in providing early prognostic indicators for multiple myeloma and mantle cell lymphoma. As the only FDA-cleared MRD assessment technology for lymphoid malignancies, clonoSEQ's accuracy and ability to guide treatment decisions could enhance patient care significantly. Multiple studies presented demonstrate clonoSEQ's potential to personalize therapy and improve outcomes based on early MRD testing results.
Read more →ADPT▼ -7.1%on this news
Adaptive Biotechnologies and Collaborators to Present More than 30 Abstracts Demonstrating the Actionability of clonoSEQ MRD Testing in Blood Cancer Patient Care and Drug Development at the 65th ASH Annual Meeting
Adaptive Biotechnologies will present more than 30 abstracts at the 65th Annual Meeting of the American Society of Hematology, focusing on the clonoSEQ MRD testing's role in blood cancer patient care and drug development. The clonoSEQ test, which is FDA-cleared, is used to detect minimal residual disease in various blood cancers and is crucial for personalizing treatment. Research findings will underline the prognostic value of MRD testing, showcasing its clinical utility and its significance in biopharmaceutical research. The company has also launched a more sensitive ctDNA-based assay aimed at improving MRD assessments in clinical trials.
Read more →ADPTAdaptive Biotechnologies Reports Third Quarter 2023 Financial Results and Provides Business Update SEATTLE
Adaptive Biotechnologies reported a net loss of $50.3 million for Q3 2023 and a 21% decrease in revenue, primarily due to challenges in their Immune Medicine division. Despite a 56% increase in clonoSEQ test deliveries, the company experienced significant revenue declines, particularly a 52% drop in Immune Medicine revenue. The firm is conducting a strategic review with Goldman Sachs to assess options for maximizing shareholder value amid these struggles. They have also adjusted their 2023 revenue guidance to exclude predictions for the Immune Medicine business.
Read more →ADPTAdaptive Biotechnologies Announces New Translational Collaboration to Measure Minimal Residual Disease with clonoSEQ Assay Across BeiGene’s Lymphoid Malignancy Pipeline
Adaptive Biotechnologies has entered a multi-year collaboration with BeiGene to utilize the clonoSEQ assay for measuring minimal residual disease (MRD) in lymphoid malignancies. This partnership aims to support the clinical development and regulatory approval of BeiGene's investigational therapies. The clonoSEQ assay's FDA clearance and its role as a prognostic tool highlight its importance in clinical trials, potentially allowing for quicker patient access to new treatments. Financial details of the agreement remain undisclosed, yet it signifies Adaptive's expanding partnerships within the pharmaceutical industry.
Read more →ADPT▲ +9.5%on this newsshared move
Adaptive Biotechnologies to Report Third Quarter Financial Results on November 9, 2023
Adaptive Biotechnologies Corporation announced that it will report its third-quarter financial results on November 9, 2023, after market close. A conference call will follow the report, commencing at 1:30 p.m. Pacific Time. The event will be accessible to investors via a live webcast on the company's website. An archive of the webcast will be available for replay within 24 hours post-event.
Read more →ADPTAdaptive Announces Launch of Epic Integration for clonoSEQ
Adaptive Biotechnologies has announced the integration of its clonoSEQ test into Epic's specialty diagnostics suite, Aura, allowing healthcare providers to order and review minimal residual disease (MRD) testing results more efficiently. The clonoSEQ test is unique in being FDA-cleared for detecting MRD in specific blood cancers, which aids in tracking patient responses to treatment. This partnership is aimed at enhancing the convenience of patient care by providing real-time insights into disease status directly within the patient's electronic health records. The company anticipates that this integration will significantly expand the accessibility and use of clonoSEQ in clinical settings.
Read more →ADPTAdaptive Biotechnologies to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
Adaptive Biotechnologies Corporation announced its participation in the Morgan Stanley 21st Annual Global Healthcare Conference, scheduled for September 13th in New York. The company aims to present its innovations related to the adaptive immune system, highlighting its potential in disease diagnosis and treatment. A live and archived webcast of the presentation will be available on the company’s website for interested investors.
Read more →ADPTAdaptive Biotechnologies Reports Second Quarter 2023 Financial Results SEATTLE
Adaptive Biotechnologies reported its Q2 2023 financial results, demonstrating a 12% revenue increase year-over-year, reaching $48.9 million. The company witnessed a 52% growth in clonoSEQ test volume and celebrated the FDA's acceptance of an IND application in cancer cell therapy. However, it reported a net loss of $47.8 million, although this was an improvement from the previous year. The company is focused on operational efficiencies and is optimistic about future growth in its MRD and Immune Medicine sectors.
Read more →ADPT▲ +8.3%on this news· ran to +22% by day 3
Adaptive Biotechnologies to Report Second Quarter Financial Results on August 2, 2023
Adaptive Biotechnologies Corporation will release its second quarter financial results on August 2, 2023, after market close. A conference call will follow, allowing investors to gain insights directly from company management. The company's commitment to leveraging the adaptive immune system for medical advancements underscores its strategic focus in the biotechnology sector.
Read more →ADPT▲ +5.8%on this news
Adaptive Biotechnologies Highlights New Data at ASCO 2023 and EHA 2023 Underscoring the clonoSEQ Assay’s Impact as a Standard for Minimal Residual Disease Assessment in Patients with Hematologic Cancer
Adaptive Biotechnologies presented new data at the ASCO 2023 and EHA 2023 regarding the clonoSEQ Assay, which emphasizes its role as a standard in minimal residual disease (MRD) assessment for patients with hematologic cancers. The data reveals clonoSEQ's effectiveness in predicting patient outcomes such as overall survival and progression-free survival, as well as its superiority over traditional detection methods. The assay has been integral in clinical trials, showing the potential to personalize cancer treatment and mitigate unnecessary therapy durations based on MRD status. Presentations at these congresses reinforce clonoSEQ's impact and clinical significance in managing hematologic malignancies.
Read more →ADPT▲ +6.4%on this news
Adaptive Biotechnologies to Participate in Upcoming June Investor Conferences
Adaptive Biotechnologies Corporation announced its participation in two upcoming investor conferences: the William Blair 43rd Annual Growth Stock Conference on June 7th, and the Goldman Sachs 44th Annual Global Healthcare Conference on June 12th. These events present opportunities for the company to showcase its advancements in immune medicine and engage with investors. Adaptive Biotechnologies is dedicated to translating the genetics of the adaptive immune system into effective clinical products for diagnosing and treating various diseases.
Read more →ADPTAdaptive Biotechnologies to Participate in the 2023 RBC Capital Markets Global Healthcare Conference
Adaptive Biotechnologies Corporation announced its participation in the 2023 RBC Capital Markets Global Healthcare Conference scheduled for May 16th in New York. The company aims to leverage this opportunity to communicate its innovative technology focused on the adaptive immune system. Stakeholders can access the live and archived webcast of the presentation via the company's website. This event could potentially increase Adaptive Biotechnologies' visibility and strengthen relationships within the healthcare investment community.
Read more →ADPT▲ +6.2%on this newsshared move
Adaptive Biotechnologies Announces FDA Acceptance of Genentech’s Investigational New Drug Application for the First Neoantigen-Directed T-Cell Therapy Product in Oncology
Adaptive Biotechnologies announced that the FDA has accepted an IND application for a T-cell receptor (TCR) based therapy developed in collaboration with Genentech. This milestone marks the first TCR-based therapeutic product to enter clinical development as part of their partnership focused on personalized cancer treatment. The collaboration aims to combine Genentech's expertise in cancer immunotherapy with Adaptive's T-cell receptor discovery platform, potentially leading to groundbreaking advancements in the treatment of solid tumors.
Read more →ADPT▲ +6.2%on this newsshared move
Adaptive Biotechnologies Announces FDA Acceptance of Genentech s Investigational New Drug Application for the First Neoantigen-Directed T-Cell Therapy Product in Oncology - The T-Cell Therapy product candid
Adaptive Biotechnologies announced that the FDA has accepted an IND application from Genentech for the first neoantigen-directed T-cell therapy. This marks a significant advancement in oncology, as the therapy utilizes Adaptive's TCR discovery platform. The collaboration aims to develop tailored treatments for solid tumors, showcasing the potential of immune medicine. Moreover, Adaptive maintains its revenue guidance for the year, indicating a stable financial outlook.
Read more →ADPT▲ +7%on this news
Adaptive Biotechnologies Reports First Quarter 2023 Financial Results SEATTLE
Adaptive Biotechnologies reported its financial results for Q1 2023, showing a 3% decrease in revenue to $37.6 million compared to Q1 2022. Notably, clonoSEQ test volume grew by 57%, but Immune Medicine revenue declined by 22%. The company is optimistic about achieving its annual goals and announced a new collaboration with Takeda. Despite posting a net loss, there was a slight improvement in losses compared to the previous year.
Read more →ADPT▼ -9.8%on this news
Adaptive Biotechnologies to Participate in the BofA Securities 2023 Healthcare Conference
Adaptive Biotechnologies Corporation announced its participation in the BofA Securities 2023 Healthcare Conference, scheduled for May 9th in Las Vegas. The company's management will take part in a fireside chat at 5:00 PM Pacific Time, offering insights into their work in harnessing the adaptive immune system. Interested individuals can access the presentation via a webcast on the company's investor relations page. This event aims to showcase Adaptive's advancements in diagnostics and treatment of various diseases.
Read more →ADPTAdaptive Biotechnologies Announces Translational Collaboration with Takeda to Measure Minimal Residual Disease with Its clonoSEQ Assay Across Its Hematologic Malignancy Pipeline
Adaptive Biotechnologies has announced a translational collaboration with Takeda to utilize its clonoSEQ Assay for measuring minimal residual disease (MRD) in clinical trials focused on lymphoid malignancies. This collaboration aims to enhance the development of novel oncological therapies, with MRD serving as a key endpoint in evaluating treatment responses. The clonoSEQ Assay, the only FDA-approved test for MRD in certain hematological cancers, is recognized for its accuracy and sensitivity. Financial terms of the collaboration have not been disclosed, but Adaptive is expected to benefit from an upfront payment and milestone payments as they progress.
Read more →ADPTAdaptive Biotechnologies to Report First Quarter Financial Results on May 3, 2023
Adaptive Biotechnologies Corporation has announced that it will report its financial results for the first quarter of 2023 after market close on May 3, 2023. A conference call will be hosted by the company management, accessible via webcast. The company is recognized for its focus on the genetics of the adaptive immune system and its applications in diagnosing and treating diseases. This financial report may provide insights into the company's performance in its commercial and clinical efforts.
Read more →ADPTAdaptive Biotechnologies to Participate in the 43rd Annual Cowen Healthcare Conference
Adaptive Biotechnologies Corporation (Nasdaq: ADPT) will participate in the 43rd Annual Cowen Healthcare Conference in Boston, scheduled for March 6th, 2023. The management team will host a fireside chat, which can be accessed via live and archived webcast on the company's website. The company's focus is on leveraging the adaptive immune system for the development of clinical products aimed at diagnosing and treating various diseases.
Read more →ADPTAdaptive Biotechnologies Reports Fourth Quarter and Full Year 2022 Financial Results SEATTLE
Adaptive Biotechnologies reported a strong financial performance for Q4 and full year 2022, with 20% revenue growth and significant test volume increases. The CEO expressed optimism about the company's momentum moving into 2023, bolstered by a robust financial position with $498.2 million in cash. Despite the positives, the company still reported notable net losses and ongoing negative EBITDA. Long-term guidance includes expectations for continued revenue growth and improved operational efficiency.
Read more →ADPTAdaptive Biotechnologies to Report Fourth Quarter and Full Year 2022 Financial Results on February 14, 2023
Adaptive Biotechnologies Corporation announced that it will report its financial results for the fourth quarter and full year 2022 after market close on February 14, 2023. The company will host a conference call starting at 1:30 PM Pacific Time to discuss these results. Live audio will be available on the company's website, and the webcast will be archived for later access. This announcement reflects Adaptive's commitment to transparency as a commercial-stage biotechnology company focused on immune system-related diagnosis and treatment.
Read more →ADPTAdaptive Biotechnologies to Present at the 41st Annual J.P. Morgan Healthcare Conference
SEATTLE, Dec. 27, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat dis
Read more →ADPTAdaptive Biotechnologies Highlights New Data Showcasing the Clinical Utility of clonoSEQ MRD Testing in Patients with Blood Cancers at the 64th ASH Annual Meeting
Multiple presentations reinforce clonoSEQ’s ability to provide valuable insights for treatment surveillance and clinical decision-making More than 30 clonoSEQ-related abstracts to be presented at the meeting SEATTLE, Dec. 10, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Co
Read more →ADPT▼ -7.9%on this news
Adaptive Biotechnologies and Collaborators to Present More than 30 Abstracts Demonstrating the Clinical Utility and Benefit of clonoSEQ MRD Testing in Blood Cancer Patients at 2022 ASH Annual Meeting
SEATTLE, Dec. 05, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), together with its collaborators, will present data from more than 30 abstracts showcasing the benefit of Adaptive’s next-generation sequencing (NGS)-based clonoSEQ® Assay in measuring
Read more →ADPTAdaptive Biotechnologies Announces Launch of clonoSEQ to Assess Minimal Residual Disease (MRD) in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Using Circulating Tumor DNA (ctDNA)
clonoSEQ is the first and only MRD test in DLBCL with Medicare coverage across all lines of therapy, treatment regimens, and timepoints Adaptive now accepts blood samples from DLBCL patients in Streck® tubes that stabilize ctDNA SEATTLE, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Adapti
Read more →ADPTAdaptive Biotechnologies to Participate in the Piper Sandler Healthcare Conference
SEATTLE, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat dis
Read more →ADPTAdaptive Biotechnologies Reports Third Quarter 2022 Financial Results SEATTLE
Adaptive Biotechnologies Reports Third Quarter 2022 Financial Results SEATTLE, Nov. 3, 2022 (GLOBE NEWSWIRE) Adaptive Biotechnologies Corporation ( Adaptive Biotechnologies ) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adap
Read more →ADPTAdaptive Announces Partnership with Epic to Increase Access to Minimal Residual Disease (MRD) Monitoring in Blood Cancers
SEATTLE, Oct. 11, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced a partn
Read more →ADPTAdaptive Biotechnologies to Report Third Quarter of 2022 Financial Results on November 3, 2022
SEATTLE, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that translates the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report
Read more →ADPTsolutions and extensive global team resources to help build world-class healthcare companies. OrbiMed's team of over 130 professionals is based in New York City, San Francisco, Shanghai, Hong Kong, Mumbai, Herzliya, and
Adaptive Biotechnologies Announces Non-Dilutive Royalty Financing with OrbiMed for Up to $250 Million SEATTLE, September 12, 2022 -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that translates the genetics of the adaptive immune
Read more →ADPTAdaptive Biotechnologies Announces Non-Dilutive Royalty Financing with OrbiMed for Up to $250 Million
SEATTLE, Sept. 12, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that translates the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it has entere
Read more →ADPTAdaptive Biotechnologies to Participate in the Morgan Stanley Global Healthcare Conference
SEATTLE, Sept. 02, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat di
Read more →ADPTAdaptive Biotechnologies Reports Second Quarter 2022 Financial Results SEATTLE
Adaptive Biotechnologies Reports Second Quarter 2022 Financial Results SEATTLE, August 3, 2022 (GLOBE NEWSWIRE) - Adaptive Biotechnologies Corporation ("Adaptive Biotechnologies") (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the
Read more →ADPTAdaptive Biotechnologies Receives Expanded Medicare Coverage of clonoSEQ for Monitoring Minimal Residual Disease in Diffuse Large B-Cell Lymphoma
SEATTLE, July 28, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced that Pa
Read more →ADPTAdaptive Biotechnologies to Report Second Quarter of 2022 Financial Results on August 3, 2022
SEATTLE, July 08, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT) a commercial-stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will
Read more →ADPT▲ +11%on this news
Adaptive Biotechnologies Launches T-Detect™ Lyme, A New T-Cell Clinical Test for the Detection of Early Lyme Disease
SEATTLE, June 15, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced the lau
Read more →ADPT▲ +9.5%on this news
Adaptive Biotechnologies Included in Key Abstracts at ASCO 2022 Supporting the Role of the clonoSEQ Assay as a Standard for MRD Assessment Technology
SEATTLE, June 02, 2022 (GLOBE NEWSWIRE) -- Data from Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, will be inclu
Read more →ADPTAdaptive Biotechnologies Reports First Quarter 2022 Financial Results SEATTLE
Adaptive Biotechnologies Reports First Quarter 2022 Financial Results SEATTLE, May 4, 2022 (GLOBE NEWSWIRE) - Adaptive Biotechnologies Corporation ("Adaptive Biotechnologies") (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the ada
Read more →ADPTAdaptive Biotechnologies to Present at the BofA Securities 2022 Healthcare Conference
SEATTLE, May 02, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat dise
Read more →ADPT▼ -6.7%on this news
Adaptive Biotechnologies to Report First Quarter Financial Results on May 4, 2022
SEATTLE, April 05, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT) a commercial-stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it wil
Read more →ADPT▲ +9.6%on this news
Adaptive Biotechnologies Appoints Tycho Peterson as Chief Financial Officer, Reorganizes and Streamlines Workforce to Drive Growth in Two Key Business Areas
SEATTLE, March 09, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial-stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced the ap
Read more →ADPT▼ -6%on this news· ran to -18% by day 3
Adaptive Biotechnologies to Present at the 42nd Annual Cowen Healthcare Conference
SEATTLE, March 02, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat di
Read more →ADPT▼ -5.5%on this news
Adaptive Biotechnologies Announces New Data Demonstrating ImmunoSEQ Technology Can Identify T-Cell Receptors Associated with Crohn’s Disease
Data being presented at the 17th European Crohn’s and Colitis Organisation (ECCO) exhibit the use of Adaptive’s ImmunoSEQ® technology to successfully identify T-cell receptors (TCR) associated with Crohn’s disease using blood samples Findings support the importance of identifyin
Read more →ADPTAdaptive Biotechnologies Reports Fourth Quarter and Full Year 2021 Financial Results SEATTLE
Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2021 Financial Results SEATTLE, Feb. 15, 2022 (GLOBE NEWSWIRE) - Adaptive Biotechnologies Corporation ("Adaptive Biotechnologies") (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the ge
Read more →ADPT▼ -5.8%on this news
Adaptive Biotechnologies to Present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
SEATTLE, Feb. 02, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat dis
Read more →ADPTAdaptive Biotechnologies to Report Fourth Quarter and Full Year 2021 Financial Results on February 15, 2022
SEATTLE, Jan. 24, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will
Read more →ADPT▼ -5.3%on this news· ran to -16% by day 3
Adaptive Biotechnologies Announces Preliminary, Unaudited 2021 Revenue Results and CFO Transition
SEATTLE, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT) today reported preliminary, unaudited revenue for the year ended December 31, 2021. Total revenue for the year ended December 31, 2021 is estimated to be in the range of $153 million to
Read more →ADPT▼ -5.3%on this news· ran to -16% by day 3
business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations. In some cases, you can identify forward-looking statements by the words "may," "will," "c
Adaptive Biotechnologies Announces Preliminary, Unaudited 2021 Revenue Results and CFO Transition SEATTLE, Jan. 10, 2022 (GLOBE NEWSWIRE) - Adaptive Biotechnologies Corporation (Nasdaq: ADPT) today reported preliminary, unaudited revenue for the year ended December 31, 2021. Tot
Read more →ADPTAdaptive Biotechnologies to Present Virtually at the 40th Annual J.P. Morgan Healthcare Conference
SEATTLE, Dec. 29, 2021 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat dis
Read more →ADPTAdaptive Biotechnologies Announces New Data Demonstrating the Benefit of Serial MRD Testing with the clonoSEQ Assay in Patients with Blood Cancers at the 63rd ASH Annual Meeting
Analysis of the MASTER trial (Abstract 481) showed clonoSEQ’s ability to measure deep and durable responses and permit treatment discontinuation in multiple myeloma patients Data in more than 30 abstracts supports clonoSEQ as a standard of care in blood cancers, delivering relev
Read more →ADPTAdaptive Biotechnologies and Collaborators to Present More than 30 Abstracts on Utility of clonoSEQ in MRD Testing in Blood Cancer Patients at the 63rd ASH Annual Meeting
SEATTLE, Dec. 02, 2021 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, together with its colla
Read more →ADPTAdaptive Biotechnologies Receives Updated Medicare Coverage for its Minimal Residual Disease (MRD) Assay, clonoSEQ for Blood Cancer Patients
Local coverage determination (LCD) confirms access to the only FDA-cleared in vitro diagnostic to detect and monitor minimal residual disease (MRD) from bone marrow and blood sample types in certain blood cancers LCD supports the expansion of coverage for additional clonoSEQ ind
Read more →ADPTAdaptive Biotechnologies Reports Third Quarter 2021 Financial Results SEATTLE
Adaptive Biotechnologies Reports Third Quarter 2021 Financial Results SEATTLE, Nov. 3, 2021 (GLOBE NEWSWIRE) - Adaptive Biotechnologies Corporation ("Adaptive Biotechnologies") (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the ad
Read more →ADPTAdaptive Biotechnologies to Report Third Quarter Financial Results on November 3, 2021
SEATTLE, Oct. 06, 2021 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will
Read more →ADPTAdaptive Biotechnologies Presents New Data During IDWeek Demonstrating the Capability of Its Immune Medicine Platform to Distinguish Between SARS-CoV-2 Infection and Vaccine Response and Detect Lyme Disease
Real-world data show T-Detect™ COVID can detect prior SARS-CoV-2 infection nearly 12 months after initial diagnosis in some patients New research demonstrates T-cell testing using T-cell receptor (TCR) repertoire characterization can distinguish natural SARS-CoV-2 infection from
Read more →ADPTAdaptive Biotechnologies Launches Enhanced clonoSEQ Assay Reports for Patients with Chronic Lymphocytic Leukemia, Now Featuring IGHV Mutation Status
SEATTLE, Sept. 30, 2021 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, announced today the la
Read more →ADPTAdaptive Biotechnologies Announces Grand Opening of State-of-the-Art Headquarters and Expands Footprint in Seattle
SEATTLE, Sept. 21, 2021 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, announced today the op
Read more →ADPTAdaptive Biotechnologies to Present New SARS-CoV-2 Data from its Immune Medicine Platform During IDWeek 2021
SEATTLE, Sept. 16, 2021 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, will be presenting dat
Read more →ADPTAdaptive Biotechnologies to Present at the Morgan Stanley Global Healthcare Conference
SEATTLE, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT) a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will
Read more →ADPTAdaptive Biotechnologies Appoints Nitin Sood as Chief Commercial Officer
SEATTLE, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced the app
Read more →ADPTAdaptive Biotechnologies Reports Second Quarter 2021 Financial Results SEATTLE
Adaptive Biotechnologies Reports Second Quarter 2021 Financial Results SEATTLE, Aug. 4, 2021 (GLOBE NEWSWIRE) - Adaptive Biotechnologies Corporation ("Adaptive Biotechnologies") (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the a
Read more →ADPTAdaptive Biotechnologies to Report Second Quarter Financial Results on August 4, 2021
SEATTLE, July 12, 2021 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT) a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will
Read more →ADPTAdaptive Biotechnologies Included in More than 20 Abstracts at ASCO and EHA 2021 Highlighting Expanding Use Cases for MRD Testing with the clonoSEQ Assay in Blood Cancer Patients
SEATTLE, June 03, 2021 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, will be included in mor
Read more →ADPTAdaptive Biotechnologies to Participate in Upcoming June 2021 Investor Conferences
SEATTLE, May 20, 2021 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT) a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will b
Read more →ADPTAdaptive Biotechnologies Reports First Quarter 2021 Financial Results SEATTLE
Adaptive Biotechnologies Reports First Quarter 2021 Financial Results SEATTLE, May 5, 2021 (GLOBE NEWSWIRE) - Adaptive Biotechnologies Corporation ("Adaptive Biotechnologies") (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the ada
Read more →ADPTAdaptive Biotechnologies to Present at the BofA Securities 2021 Virtual Healthcare Conference
SEATTLE, April 27, 2021 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT) a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will
Read more →ADPTAdaptive Biotechnologies to Report First Quarter Financial Results on May 5, 2021
SEATTLE, April 12, 2021 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT) a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it wil
Read more →ADPTAdaptive Biotechnologies Strengthens Expertise and Diversity of Board of Directors with Appointments of Leslie Trigg and Katey Owen SEATTLE
Adaptive Biotechnologies Strengthens Expertise and Diversity of Board of Directors with Appointments of Leslie Trigg and Katey Owen SEATTLE, March 17, 2021 - Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the
Read more →ADPTAdaptive Biotechnologies Announces FDA Emergency Use Authorization for T-Detect™ COVID to Confirm Recent or Prior COVID-19 Infection
First and only clinical T cell-based test for patients to detect the unique T-cell signature specific to SARS-CoV-2, the virus that causes COVID-19 T-Detect COVID correctly confirmed recent or prior COVID-19 infections 97.1% of the time from date of RT-PCR diagnosis with 100% sp
Read more →ADPTAdaptive Biotechnologies to Present at the Cowen 41st Annual Healthcare Conference
SEATTLE, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT) a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will
Read more →ADPTAdaptive Biotechnologies Reports Fourth Quarter and Full Year 2020 Financial Results SEATTLE
Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2020 Financial Results SEATTLE, Feb. 24, 2021 (GLOBE NEWSWIRE) - Adaptive Biotechnologies Corporation ("Adaptive Biotechnologies") (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the ge
Read more →ADPTAdaptive Biotechnologies Launches T-Detect™ COVID, First Clinical T-Cell Based Test for Patients to Confirm Recent or Prior COVID-19 Infection
T-Detect is currently under review by the U.S. Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) Patients can conveniently opt to visit one of nearly 2,000 Labcorp sites or arrange for a mobile phlebotomy service at their home SEATTLE, Feb. 23, 2021 (GLOB
Read more →ADPTAdaptive Biotechnologies Expands Collaboration with Labcorp to Increase Access to Growing Research and Clinical Diagnostic Portfolio
SEATTLE, Feb. 23, 2021 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced an expa
Read more →ADPTAdaptive Biotechnologies to Report Fourth Quarter and Full Year 2020 Financial Results on February 24, 2021
SEATTLE, Feb. 02, 2021 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT) a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will
Read more →ADPTAdaptive Biotechnologies to Collaborate with AstraZeneca in Mapping the Immune Response to Cancer Antigens to Potentially Inform the Development of Novel Diagnostics and Therapeutics
Multi-year, pan-portfolio deal extends Adaptive’s proprietary immunoSEQ T-MAP offering, originally launched for COVID-19, into oncology This transaction highlights the value of immune receptor data generated by Adaptive’s proprietary immune medicine platform SEATTLE, Jan. 11, 2
Read more →ADPTAdaptive Biotechnologies to Present at the 39th Annual J.P. Morgan Healthcare Conference
SEATTLE, Dec. 30, 2020 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat dis
Read more →ADPTAdaptive Biotechnologies Announces New Clinical Data Demonstrating Impact of clonoSEQ Assay on Patients with Blood Cancers at the 62nd ASH Annual Meeting
SEATTLE, Dec. 06, 2020 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced new rea
Read more →ADPTAdaptive Biotechnologies and Collaborators to Present Data from More Than 35 Abstracts at ASH 2020 Highlighting Clinical Relevance of MRD Testing with the clonoSEQ Assay in Blood Cancer Patients
Studies reinforce clonoSEQ as standard of care in minimal residual disease (MRD) across eight disease states Real-world evidence shows treatment decisions based on precise MRD measurement directly correlate with improved patient outcomes and cost savings SEATTLE, Nov. 23, 2020
Read more →ADPTAdaptive Biotechnologies Reports Third Quarter 2020 Financial Results SEATTLE
Adaptive Biotechnologies Reports Third Quarter 2020 Financial Results SEATTLE, Nov. 10, 2020 (GLOBE NEWSWIRE) - Adaptive Biotechnologies Corporation ("Adaptive Biotechnologies") (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the a
Read more →ADPTAdaptive Biotechnologies Announces Collaboration with GSK to Measure Minimal Residual Disease with clonoSEQ Assay Across its Hematology and Oncology Portfolio
SEATTLE, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced a colla
Read more →ADPTAdaptive Biotechnologies to Report Third Quarter Financial Results on November 10, 2020
SEATTLE, Oct. 13, 2020 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT) a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will
Read more →ADPTAdaptive Biotechnologies to Present at the Morgan Stanley 2020 Healthcare Conference
SEATTLE, Sept. 01, 2020 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it wil
Read more →ADPTAdaptive Biotechnologies Reports Second Quarter 2020 Financial Results SEATTLE
Adaptive Biotechnologies Reports Second Quarter 2020 Financial Results SEATTLE, Aug. 10, 2020 (GLOBE NEWSWIRE) - Adaptive Biotechnologies Corporation ("Adaptive Biotechnologies") (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the
Read more →ADPTAdaptive Biotechnologies to Present at the UBS Genomics 2.0 and Medtech Innovations Summit
SEATTLE, Aug. 10, 2020 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will
Read more →ADPTAdaptive Biotechnologies Receives Expanded FDA Clearance for the clonoSEQ Assay to Assess Minimal Residual Disease (MRD) in Patients with Chronic Lymphocytic Leukemia
First and only FDA-cleared assay for MRD in CLL, multiple myeloma and ALL CLL clearance includes testing in blood; Adaptive collaborating with LabCorp® and Phlebotek Solutions® to provide clonoSEQ patients convenient options and safe access to blood draws at home or at LabCorp P
Read more →ADPTAdaptive Biotechnologies Launches immunoSEQ T-MAP COVID, First Molecular T Cell Monitoring Tool for SARS-CoV-2
Tailored for vaccine developers to accurately and reproducibly measure and track COVID-19 specific T-cell response in clinical trials Powered by T-cell immune response data from over 1,000 COVID-19 patients from ImmuneCODE, the largest public database mapping T-cell receptors (T
Read more →ADPTAdaptive Biotechnologies Launches National Clinical Trial to Develop Novel T-Cell Based Diagnostic for Lyme Disease
SEATTLE, July 28, 2020 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corp. (Nasdaq: ADPT) announced today the launch of ImmuneSense Lyme™, a research study to inform the development of an improved test to detect Lyme disease in the early stages of an infection, when the disease is
Read more →ADPTAdaptive Biotechnologies Announces Pricing of Public Offering of Common Stock
SEATTLE, July 15, 2020 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, announced today the pri
Read more →ADPTAdaptive Biotechnologies Announces Proposed Public Offering of Common Stock
Adaptive Biotechnologies Announces Proposed Public Offering of Common Stock SEATTLE, Wash., July 14, 2020 - Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinic
Read more →ADPTAdaptive Biotechnologies to Report Second Quarter Financial Results on August 10, 2020
SEATTLE, July 09, 2020 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT) a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will
Read more →ADPTAdaptive Biotechnologies Reports First Quarter 2020 Financial Results SEATTLE
Adaptive Biotechnologies Reports First Quarter 2020 Financial Results SEATTLE, May 12, 2020 - Adaptive Biotechnologies Corporation ("Adaptive Biotechnologies") (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune sys
Read more →ADPTAdaptive Biotechnologies to Present at the BofA Securities 2020 Healthcare Conference
SEATTLE, May 06, 2020 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will
Read more →ADPTAdaptive Biotechnologies and Microsoft launch virtual ImmuneRACE study to inform novel COVID-19 diagnostics to address unmet needs in testing LabCorp, through its Covance drug development business, will provide a safe, i
Adaptive Biotechnologies and Microsoft launch virtual ImmuneRACE study to inform novel COVID-19 diagnostics to address unmet needs in testing LabCorp, through its Covance drug development business, will provide a safe, in-person COVID-19 sample collection service from the conven
Read more →ADPTAdaptive Biotechnologies to Report First Quarter Financial Results on May 12, 2020
SEATTLE, April 27, 2020 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT) a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it wil
Read more →ADPTAdaptive Biotechnologies Expands Executive Leadership Team to Support Development and Commercialization of Clinical Products, including immunoSEQ Dx
SEATTLE, April 09, 2020 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced the addition of tw
Read more →ADPTAdaptive Biotechnologies Reports Fourth Quarter and Full Year 2019 Financial Results SEATTLE
Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2019 Financial Results SEATTLE, Feb. 26, 2020 (GLOBE NEWSWIRE) - Adaptive Biotechnologies Corporation ("Adaptive Biotechnologies") (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the ge
Read more →ADPTAdaptive Biotechnologies to Present at the 40th Annual Cowen Health Care Conference
SEATTLE, Feb. 19, 2020 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced the com
Read more →ADPTAdaptive Biotechnologies to Report Fourth Quarter and Full Year 2019 Financial Results on February 26, 2020
SEATTLE, Feb. 12, 2020 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced that it
Read more →ADPTAdaptive Announces Pricing of Public Offering of Common Stock
SEATTLE, Jan. 23, 2020 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq:ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, announced today the pric
Read more →ADPTAdaptive Announces Preliminary Unaudited Revenue for Full Year 2019
SEATTLE, Jan. 21, 2020 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq:ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, announced today prelimin
Read more →ADPTAdaptive Announces Proposed Public Offering of Common Stock
Adaptive Announces Proposed Public Offering of Common Stock SEATTLE, Wash., January 21, 2020 - Adaptive Biotechnologies Corporation (Nasdaq:ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to
Read more →ADPTAdaptive and Genentech Partner to Use clonoSEQ Assay to Measure Minimal Residual Disease as a Primary Endpoint in Phase III Study of Chronic Lymphocytic Leukemia Patients
SEATTLE, Jan. 13, 2020 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq:ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced a multi-
Read more →ADPTAdaptive Biotechnologies Receives Expanded Medicare Coverage of clonoSEQ for Monitoring MRD in Patients With Chronic Lymphocytic Leukemia
Adaptive Biotechnologies Receives Expanded Medicare Coverage of clonoSEQ for Monitoring MRD in Patients With Chronic Lymphocytic Leukemia SEATTLE, Wash., January 8, 2020 - Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to
Read more →ADPTAdaptive Biotechnologies to Present at the 38th Annual J.P. Morgan Healthcare Conference
SEATTLE, Dec. 30, 2019 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), today announced the company will be participating in the upcoming 38th Annual J.P. Morgan Healthcare Conference in San Francisco, CA. Adaptive’s managemen
Read more →ADPTAdaptive and AbbVie Partner Across Multiple Myeloma Trials to Measure Minimal Residual Disease Using the clonoSEQ Assay
SEATTLE, Dec. 09, 2019 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq:ADPT) today announced a multi-year, global collaboration agreement with AbbVie (NYSE: ABBV) to utilize Adaptive’s next-generation sequencing (NGS)-based clonoSEQ® Assay to assess minimal resid
Read more →ADPTAdaptive Biotechnologies and Collaborators to Present Data from More Than 25 clonoSEQ Abstracts at ASH 2019 Demonstrating Clinical Relevance of Standardized, Accurate MRD Testing for Blood Cancer Patients
Research and real-world evidence support the use across a range of leukemias and lymphomas and demonstrate utility in multiple tissue types, including blood and bone marrow Late breaker presentation of CANDOR study includes secondary endpoint of improved NGS MRD negative Complet
Read more →ADPTAdaptive Biotechnologies Corporation Reports Third Quarter 2019 Financial Results SEATTLE
Adaptive Biotechnologies Corporation Reports Third Quarter 2019 Financial Results SEATTLE, November 12, 2019 (GLOBE NEWSWIRE) - Adaptive Biotechnologies Corporation ("Adaptive Biotechnologies") (Nasdaq: ADPT) today reported financial results for the quarter ended September 30, 2
Read more →ADPTAdaptive Biotechnologies to Report Third Quarter Financial Results on November 12, 2019
SEATTLE, Oct. 29, 2019 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies (Nasdaq: ADPT) today announced that it will report financial results for the third quarter of 2019 after market close on Tuesday, November 12, 2019. Company management will host a corresponding conference call, b
Read more →ADPTAdaptive Biotechnologies Enters Partnership with Illumina to Develop Distributable IVD Test Kits for clonoSEQ and immunoSEQ Dx Partnership Will Enable Physicians to Order Clinical Immunodiagnostic Testing that Can Be Per
Adaptive Biotechnologies Enters Partnership with Illumina to Develop Distributable IVD Test Kits for clonoSEQ and immunoSEQ Dx Partnership Will Enable Physicians to Order Clinical Immunodiagnostic Testing that Can Be Performed in Local Laboratories SEATTLE, Wash., September 24,
Read more →ADPTAdaptive Biotechnologies Enters Partnership for Use Of clonoSEQ as Preferred MRD Test for Drug Development Across Amgen’s Hematology Franchise
SEATTLE, Sept. 17, 2019 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq:ADPT) today announced it has entered into a global agreement with Amgen for the use of Adaptive’s next-generation sequencing (NGS)-based clonoSEQ® Assay to assess minimal residual disease (MR
Read more →ADPTAdaptive Biotechnologies Corporation Reports Second Quarter 2019 Financial Results SEATTLE
Adaptive Biotechnologies Corporation Reports Second Quarter 2019 Financial Results SEATTLE, August 13, 2019 (GLOBE NEWSWIRE) Adaptive Biotechnologies Corporation ( Adaptive Biotechnologies ) (Nasdaq: ADPT) today reported financial results for the quarter ended June 30, 2019. A
Read more →ADPTAdaptive Biotechnologies Executes Lease for New 100,000 Square Foot Corporate Headquarters, Tripling its Footprint in Seattle s Growing Biotech Hub Development of the waterfront office space and research facility by Alex
Adaptive Biotechnologies Executes Lease for New 100,000 Square Foot Corporate Headquarters, Tripling its Footprint in Seattle s Growing Development of the waterfront office space and research facility by Alexandria Real Estate Equities, Inc. is underway with occupancy expected
Read more →ADPTAdaptive Biotechnologies to Report Second Quarter Financial Results on August 13, 2019
SEATTLE, Aug. 01, 2019 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies (Nasdaq: ADPT) today announced that it will report financial results for the second quarter of 2019 after market close on Tuesday, August 13, 2019. Company management will host a corresponding conference call, be
Read more →ADPTAdaptive Biotechnologies Receives New York State CLEP Approval for clonoSEQ to Detect and Monitor Minimal Residual Disease (MRD) in Patients with Certain Blood Cancers SEATTLE
Adaptive Biotechnologies Receives New York State CLEP Approval for clonoSEQ to Detect and Monitor Minimal Residual Disease (MRD) in Patients with Certain Blood Cancers SEATTLE, July 31, 2019 Adaptive Biotechnologies Corporation (Nasdaq:ADPT) ( Adaptive ), a commercial-stage bi
Read more →ADPTAdaptive Biotechnologies Announces Closing of Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
SEATTLE, July 01, 2019 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq:ADPT) (“Adaptive”), a commercial-stage biotechnology company that reads and translates the genetic code of the adaptive immune system to develop personalized diagnostics and therapeutics to im
Read more →ADPTAdaptive Biotechnologies Corporation (Nasdaq: ADPT) to Ring The Nasdaq Stock Market Opening Bell
ADVISORY, June 27, 2019 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial-stage biotechnology company that reads and translates the genetic code of the adaptive immune system to develop personalized diagnostics and therapeutics to improve pati
Read more →ADPTAdaptive Biotechnologies Announces Pricing of Initial Public Offering
Adaptive Biotechnologies Announces Pricing of Initial Public Offering SEATTLE, Wash, June 26, 2019 Adaptive Biotechnologies Corporation (Nasdaq:ADPT) ( Adaptive ), a commercial-stage biotechnology company that reads and translates the genetic code of the adaptive immune system
Read more →Competitive Position
How ADPT ranks across every disease it competes inCompetitive Position is a premium feature
See how ADPT ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial